OUTLOOK THERAPEUTICS
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
OUTLOOK THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Website Url:
http://www.outlooktherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
(609) 619-3990
Email Addresses:
[email protected]
Total Funding:
238.5 M USD
Technology used in webpage:
SPF Content Delivery Network Microsoft Exchange Online Office 365 Mail IPv6 Google Maps GoDaddy DNS Google Maps API COVID-19 Vimeo
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Syntone Ventures
Syntone Ventures investment in Post-IPO Equity - Outlook Therapeutics
Biolexis
Biolexis investment in Post-IPO Equity - Outlook Therapeutics
GMS Tenshi Holdings
GMS Tenshi Holdings investment in Post-IPO Equity - Outlook Therapeutics
Longwood Capital Partners
Longwood Capital Partners investment in Venture Round - Outlook Therapeutics
Sabby Management
Sabby Management investment in Venture Round - Outlook Therapeutics
Cormorant Global Healthcare Master Fund
Cormorant Global Healthcare Master Fund investment in Venture Round - Outlook Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Venture Round - Outlook Therapeutics
venBio Partners
venBio Partners investment in Venture Round - Outlook Therapeutics
Longwood Capital Partners
Longwood Capital Partners investment in Venture Round - Outlook Therapeutics
venBio Partners
venBio Partners investment in Venture Round - Outlook Therapeutics
Key Employee Changes
Official Site Inspections
http://www.outlooktherapeutics.com Semrush global rank: 4.59 M Semrush visits lastest month: 2.24 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Outlook Therapeutics"
Outlook Therapeutics® Announces Strategic Organizational …
Dec 6, 2023 For more information, please visit www.outlooktherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements. All statements other than …See details»
Overview - Outlook Therapeutics
Outlooktherapeutics.com WP GDPR Cookie Consent Preferences 1 year HTTP Marketing. Marketing. Marketing cookies are used to track visitors across websites. The intention is to …See details»
Outlook Therapeutics, Inc. Information - RocketReach
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of …See details»
Investor Overview - Outlook Therapeutics, Inc.
Dec 3, 2024 Corporate Profile. Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVAâ„¢ (bevacizumab-vikg) as the first FDA-approved …See details»
Corporate Presentation September 2022
NASDAQ: OTLK outlooktherapeutics.com Corporate Presentation May 2023. Enhancing the standard of care for retinal disorders by working to achieve the first FDA approval for …See details»
Outlook Therapeutics® Announces Strategic Organizational …
Dec 6, 2023 Realignment focused on supporting ONS-5010 U.S. and EU regulatory and commercial prioritiesContinued progress toward commencement of additional adequate and …See details»
Outlook Therapeutics, Inc. | LinkedIn
Outlook Therapeutics, Inc. | 9,951 followers on LinkedIn. ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO | Outlook Therapeutics is a late clinical-stage ...See details»
Outlook Therapeutics - Overview, News & Similar companies
Mar 20, 2024 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: …See details»
Outlook Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 609 619 3990 Outlook Therapeutics develops an ophthalmic formulation of bevacizumab for the treatment of wet age …See details»
Outlook Therapeutics - Craft
Outlook Therapeutics (formerly known as Oncobiologics) is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing, and commercializing complex …See details»
Outlook Therapeutics, Inc. (OTLK) - Yahoo Finance Canada
See the company profile for Outlook Therapeutics, Inc. (OTLK) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Outlook Therapeutics - Company Profile - Tracxn
Aug 31, 2024 Outlook Therapeutics - Developer of antibodies for ophthalmic disorders. Public Company. Raised a total funding of $51.8M over 14 rounds from 13 investors. Outlook …See details»
Leading Ophthalmology Organization Launches Podcast Video …
Jan 12, 2021 For more information, please visit www.outlooktherapeutics.com. Forward-Looking Statements. This press release and the podcast video to which it relates contain forward …See details»
Outlook Therapeutics® Adds Global Commercial Expertise with …
ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic …See details»
ONS-5010 / LYTENAVAâ„¢ OVERVIEW - Outlook Therapeutics
ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) — Investigational Ophthalmic Formulation of Bevacizumab ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) is an investigational ophthalmic …See details»
Outlook Therapeutics® Streamlines Operations - GlobeNewswire
6 days ago ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the …See details»
Outlook Therapeutics® to Report Financial Results for Third …
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the …See details»
Outlook Therapeutics (OTLK) Stock Price, News & Analysis
1 day ago www.outlooktherapeutics.com. Phone (609) 619-3990. Fax N/A. Employees 20. Year Founded N/A. Price Target and Rating. Average Stock Price Target $42.34. High Stock Price …See details»
Outlook Therapeutics Provides a Corporate Update and Business …
Jan 25, 2022 For more information, please visit www.outlooktherapeutics.com. Forward-Looking Statements . This press release contains forward-looking statements. All statements other …See details»
Outlook Therapeutics to reduce workforce by 23%, streamline …
6 days ago Outlook Therapeutics announced that following an internal strategic review, the management team and board of directors have implemented initiatives to streamline the …See details»